Phase I Study of GDC-0068 as a Single Agent and in Combination with Other Anticancer Drugs in Patients with Advanced Solid Tumors.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Ipatasertib (Primary)
- Indications Prostate cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 23 Feb 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
- 23 Aug 2016 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History